

2016



**GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE**

ESMO Handbook on Cancer in the Senior Patient

2ND EDITION

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

Editors and Contributors

Editors

Matti S. Aapro

Institut Multidisciplinaire d'Oncologie IMO, Clinique de Genolier, Genolier, Switzerland

Dirk Schrijvers

Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium

Contributors

Chapter 01 - Introduction

S. Rostoft - Department of Geriatric Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway

T.B. Wyller - Department of Geriatric Medicine, University of Oslo, Oslo University Hospital, Oslo, Norway

Chapter 02 - Cancer Epidemiology

D. Schrijvers - Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium

Chapter 03 - Evaluation of the Senior Cancer Patient: Comprehensive Geriatric Assessment and Screening Tools for the Elderly

M. Extermann - Senior Adult Oncology, Moffitt Cancer Center, Tampa, FL, USA

Chapter 04 - Frailty in the Elderly

M. Gosney - Royal Berkshire NHS Foundation Trust, Reading, Berkshire, UK

Chapter 05 - Surgical Treatment

P.S. Somasundar - Division of Surgical Oncology, Roger Williams Medical Center, Boston University, Providence, USA.

R.A. Audisio - U.K. University of Liverpool, Consultant Surgical Oncologist, St Helens Teaching Hospital, St Helens, U.K.

Chapter 06 - Radiotherapy in the Elderly Cancer Patient

D.C. Christoph - Department of Medical Oncology, West German Cancer Centre, University Hospital of the University Duisburg-Essen, Essen, Germany

W.E.E. Eberhardt - Department of Medical Oncology, West German Cancer Centre, University Hospital of the University Duisburg-Essen, Essen, Germany

Chapter 07 - Hormonal Anti-Cancer Treatment in the Senior Cancer Patient

B. Seruga - Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

E. Amir - Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

I.F. Tannock - Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada

Chapter 08 – Cytotoxic and Targeted Anti-Cancer Treatment in the Senior Cancer Patient

H. Wildiers – Department of General Medical Oncology and Multidisciplinary Breast Centre, University Hospitals Leuven, Belgium

Chapter 09 - Diffuse Large B-Cell Lymphoma in the elderly: R-CHOP or adapted strategy?

C. Sarkozy - Department of Haematology, Hospices Civils de Lyon, Lyon, France.

B. Coiffier - Department of Haematology, Hospices Civils de Lyon, Lyon, France.

Chapter 10 - Management of Chronic Myeloproliferative Neoplasia (MPN) in Elderly Patients

D. Wolf - Internal Medicine III, Oncology, Hematology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany and Internal Medicine V, Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria

R. Stauder - Internal Medicine V, Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria

Chapter 11 - Myelodysplastic Syndromes in the Senior Patient

R. Stauder - Department of Internal Medicine V, Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria

Chapter 12 - Breast Cancer in the Senior Patient

A.R. Mislani and L. Biganzoli - Medical Oncology Department, Nuovo Ospedale Santo Stefano, Istituto Tumori Toscano, Prato, Italy

Chapter 13 - Lung Cancer in the Senior Patient

D. Schrijvers - Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium

Chapter 14 – Treatment of Colorectal Cancer in the Senior Patient

D. Papamichael – Department of Medical Oncology, B.O. Cyprus Oncology Centre, Nicosia, Cyprus

Z. Kordatou – Department of Medical Oncology, B.O. Cyprus Oncology Centre, Nicosia, Cyprus

Chapter 15 - Prostate Cancer

Helen J Boyle - Department of Medical Oncology, Centre Léon-Bérard and University Claude-Bernard, Lyon 1 University, Lyon, France.

J.P. Droz - Research Unit, Cancer and Environment, Centre Léon-Bérard and University Claude-Bernard, Lyon 1 University, Lyon, France.

Chapter 16 - Bladder Cancer in the elderly

N. Mottet – Urology Department, Jean Monnet University, St Etienne, France.

Chapter 17 - Gynaecological Cancer in the Senior Patient

O. Zivanovic - Department of Surgery, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA

S.M. Lichtman - Department of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, USA

Chapter 18 – Head and Neck Cancer in the Elderly

Ada S. Kougioumtzopoulou - Radiotherapist, Radiotherapy Unit, 2nd Department of Radiology, Athens School of Medicine, Athens, Greece

Anastasios Dimou - 3rd Department of Medicine, Athens Medical School & Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA

Kostas N. Syrigos - Professor of Medicine & Oncology, Chair, 3rd Department of Medicine, University of Athens Medical School, Sotiria General Hospital, Athens, Greece

Chapter 19 - Renal Cell Cancer

A. P. Fay - PUCRS School of Medicine, Porto Alegre, Brazil
J. Bellmunt - Department of medicine, Dana-Farber Cancer Institute, Boston, United States; Department of Medical Oncology, University Hospital del Mar-IMIM, Barcelona, Spain.

Chapter 20 - Psychological Problems in Older Cancer Patients

I.K. Avildsen - Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

J.C. Emanu - Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

M. I. Weinberger - Department of Psychiatry, Weill Cornell Medical College, White Plains, New York, U.S.A.

A. J. Roth - Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

C.J. Nelson - Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

Chapter 21 - Social and Ethical Aspects

A. Pugliesi Rinaldi - Division of Medical Oncology, Dept. of Medical Specialties, University Hospitals of Geneva, Geneva, Switzerland

G.B. Zulian - Dept. of Re-adaptation and Palliative Medicine, University Hospitals of Geneva, Geneva, Switzerland

Chapter 22 - The Role of the Multidisciplinary Team

L. Balducci - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, U.S.A.

Declarations of Interest

Chapter 1: Dr Rostoft has reported no conflicts of interest. Dr Wyller has reported no conflicts of interest.

Chapter 2: Dr Schrijvers has not reported any conflicts of interest.

Chapter 3: Prof Extermann has reported no conflicts of interest.

Chapter 4: Dr Gosney has reported no conflicts of interest.

Chapter 5: R.A. Audisio and P.S. Somasundar have reported no conflict of interest.

Chapter 6: Dr Christoph has reported: speakers' bureau for Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, Roche.

Dr Eberhardt has reported: advisory boards for Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Lilly, Merck, Roche, Novartis, Daiichi Sankyo, Astra Zeneca, Hexal, Astellas and honoraria from educational lectures from Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Lilly, Merck, Roche, Novartis, Astra Zeneca, Hexal.

Chapter 7: Dr Tannock has advised a number of companies including Sanofi, Janssen and Ipsen Pharma about clinical trials for prostate cancer, for which he receives donations to his research fund.

Dr Seruga has reported no conflicts of interest.

Dr Amir has reported no conflicts of interest.

Chapter 8: Dr. Wildiers has reported no conflicts of interest.

Chapter 9: Dr. Sarkozy has reported no conflicts of interest.

Prof. Coiffier has reported no conflicts of interest.

Chapter 10: Dr Stauder has reported that he is on the advisory board for Celgene and has received honoraria from Celgene, Teva and Novartis. He has also received research support from Celgene and Teva.

Dr Wolf has reported that he received speaker's honorary from BMS, Novartis, Ariad, Pfizer, Amgen, Lilly, MSD, and AOP Pharma. He also conducts research supported by Novartis, Ariad, Pfizer, and AOP Pharma.

Chapter 11: Dr Stauder has reported no potential conflicts of interest in relation to this chapter.

Chapter 12: Dr Biganzoli has reported no conflicts of interest. Dr Mislav has reported no conflicts of interest.

Chapter 13: Dr Schrijvers has not reported any conflicts of interest.

Chapter 14: D. Papamichael has not reported any conflicts of interest. Z. Kordatou has not reported any conflicts of interest.

Chapter 15: Dr Boyle has received travel grants from Sanofi Jansen and Astellas, and honoraria for meetings from Sanofi.

Dr Droz has reported that he has received travel grants from Sanofi and is a member of the speaker's bureau for Sanofi.

Chapter 16: Prof Mottet has reported that he conducts research supported by Astellas, Pierre Fabre and Sanofi Pasteur. He has also declared being a consultant for Astellas, Bristol-Myers Squibb, Pierre Fabre and Sanofi Pasteur.

Chapter 17: Dr Zivanovic and Dr Lichtman have reported no conflicts of interest.

Chapter 18: Ada S. Kouglioumtzopoulou, Anastasios Dimou, and Kostas N. Syrigos have reported no conflicts of interest.

Chapter 19: Dr Fay has reported no conflict of interest.

Dr Bellmunt has reported that he is a member of Advisory Boards for Bayer HealthCare, Pfizer, Novartis and Roche. He is also a consultant for Bayer HealthCare and Pfizer.

Chapter 20: Dr Roth, Dr Weinberger, Dr Balk, and Dr Nelson have reported no conflicts of interest.

Chapter 21: Dr Pugliesi Rinaldi and Dr Zulian and have not reported any conflicts of interest.

Chapter 22: L. Balducci has reported no conflicts of interest

TABLE OF CONTENTS

Editors and Contributors.....	i
Editors.....	i
Contributors	i
Declarations of Interest	iv
Chapter 01 – Introduction.....	1
Defining the Elderly.....	1
Biology of Ageing and Changes in Organ Function	1
Changes in Cognition.....	2
Cancer and Ageing	2
Clinical Aspects.....	3
Further Reading	6
Chapter 02 - Cancer Epidemiology	7
Introduction	7
Population Demographics	7
Cancer Demographics	8
Society-Related Problems.....	9
Conclusions	9
Further Reading	9
Chapter 3 - Evaluation of the Senior Cancer Patient: Comprehensive Geriatric Assessment and Screening Tools for the Elderly.....	11
Introduction	11
Short Screening Tools	12
Comprehensive Geriatric Assessment.....	13
Tools to Help Decision Making.....	15
Conclusion	17
Further Reading	17
Chapter 04 – Frailty in the Elderly	19
Introduction	19
Assessment of Frailty.....	20
Frailty as a Predictor	20
Conclusion	22

Further Reading	23
Chapter 05 - Surgical Treatment	24
Introduction	24
Assessing Senior Patients	24
Surgical Resection	27
Postoperative Care	29
Tumour Biology	29
Conclusion	30
Further Reading	30
Chapter 06 - Radiotherapy in the Elderly Cancer Patient.....	31
Indications for Radiotherapy in the Elderly.....	31
Side Effects of Radiotherapy in the Elderly (Acute and Late).....	32
Efficacy and Outcome of Radiotherapy in the Ageing.....	34
Palliative Setting: Toxicity and Efficacy Ratio.....	35
Curative Setting: Combinations of Chemotherapy and Radiotherapy	36
Conclusions	37
Further Reading	38
Chapter 07 - Hormonal Anti-Cancer Treatment in the Senior Cancer Patient.....	39
Introduction	39
Breast Cancer.....	39
Prostate Cancer	44
Further Reading	49
Chapter 08 – Cytotoxic and Targeted Anti-Cancer Treatment in the Senior Cancer Patient	51
Introduction	51
Chemotherapy in Senior Adults	51
Targeted Therapies in Senior Adults.....	54
Further Reading	56
Chapter 09 - Diffuse Large B-Cell Lymphoma in the Elderly: R-CHOP or Adapted Strategy?.....	57
Introduction	57
Initial Clinical and Biological Evaluation of Patients and the Disease	57
Treatment: First-Line Strategy	59

Treatment: At Relapse	63
Conclusion	64
Further Reading	64
Chapter 10 - Management of Chronic Myeloproliferative Neoplasia (MPN) in Elderly Patients	67
Diagnosis and Classification of Myeloproliferative Disorders	67
Treatment Strategies of Chronic Myeloid Leukaemia (CML) in the Senior Patient	70
Treatment Strategies of Polythemia Vera (PV) in the Senior Patient	72
Treatment Strategies of Essential Thrombocytosis (ET) in the Senior Patient.....	73
Treatment Strategies of Primary Myelofibrosis (PMF) in the Senior Patient	74
Conclusions	74
Further Reading	75
Chapter 11 - Myelodysplastic Syndromes in the Senior Patient.....	77
The Relevance of Myelodysplastic Syndromes in the Elderly	77
Classification and Risk Scoring in MDS	77
Age-Adjusted Models and Assessment in Elderly MDS Patients	78
Treatment Options in Elderly MDS Patients.....	79
Future Perspectives	81
Further Reading	82
Chapter 12 - Breast Cancer in the Senior Patient	84
Introduction	84
Early Breast Cancer	84
Locally Advanced Breast Cancer	86
Metastatic Breast Cancer	86
Conclusion	88
Further Reading	88
Chapter 13 – Lung Cancer in the Elderly	90
Introduction	90
Early Non-Small-Cell Lung Cancer in the Elderly.....	90
Advanced Non-Small-Cell Lung Cancer in the Elderly	92
Small-Cell Lung Cancer in the Elderly	95
Palliative Treatment in Elderly Lung Cancer Patients	96
Conclusion	96

Further Reading	96
Chapter 14 – Treatment of Colorectal Cancer in the Senior Patient	98
Introduction	98
Adjuvant Treatment.....	98
Metastatic Disease.....	99
Rectal Cancer	100
Conclusions	101
Further Reading	101
Chapter 15 - Prostate Cancer	103
Introduction and General Background	103
Epidemiology	103
Diagnosis and Staging.....	103
Prognosis	103
Treatment.....	104
Conclusion	108
Further Reading	108
Chapter 16 – Bladder Cancer in the Elderly	110
Incidence and Mortality	110
Aetiology and Risk Factors	110
Pathology	110
Natural History and Tumour Biology	110
Signs and Symptoms	111
Imaging, Cystoscopy, and Urinary Cytopathology	111
Staging.....	111
Treatment of Bladder Cancer.....	113
Further Reading	117
Chapter 17 – Gynaecological Cancer in the Senior Patient	119
Introduction	119
Cervical Cancer	119
Uterine Cancer.....	122
Special Types of Endometrial Malignancy	124
Vaginal Cancer	125

Vulvar Cancer	127
Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.....	128
Conclusion	131
Further Reading	131
Chapter 18 – Head and Neck Cancer in the Elderly.....	133
Introduction	133
Surgery	133
Radiotherapy.....	134
Chemoradiation.....	134
Chemotherapy and Targeted Therapies	135
Geriatric Assessment.....	136
Conclusions	136
Further Reading	136
Chapter 19 - Renal Cell Cancer	138
Introduction	138
Surgery in the Senior Cancer Patient.....	138
Systemic Therapy of Metastatic Renal Cell Carcinoma in the Senior Cancer Patient	139
Patient-Focused Approach.....	143
Conclusion	146
Further Reading	146
Chapter 20 - Psychological Problems in Older Cancer Patients	148
Introduction	148
Depression.....	148
Anxiety	151
Conclusions	153
Further Reading	153
Chapter 21 - Social and Ethical Aspects	155
Introduction	155
Respect.....	156
Admiration.....	156
Attention.....	157
Information.....	157

Protection.....	157
Diagnosis	157
Care	158
Time.....	159
Caution	159
Freedom.....	159
Further Reading	160
Chapter 22 - The Role of the Multidisciplinary Team	161
Introduction	161
The Assessment of Age.....	162
Polypharmacy	163
Management of the Caregiver.....	165
Function of the Team	166
Conclusions and Perspectives	167
Further Reading	167